Publication | Closed Access

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

UrologyMedicinePharmacologyClinical TrialsPharmacotherapyCancer TreatmentProstatic DiseaseOncology